🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

10/ Conclusion: Among patients with STEMI undergoing primary PCI with radial access, bivalirudin with a median 3h post-PCI high-dose infusion reduced 30-day all-cause death and BARC types 3-5 major bleeding compared with heparin monotherapy. Published in today’s Lancet.

One more RCT showing better prognosis after imaging-guided PCI vs standard angio-guided PCI. What are we waiting for? #updateguidelines #cardiotwitter

New SWEDEHEART study shows that using intracoronary imaging during percutaneous coronary intervention for proximal coronary artery lesions reduces the risk of target lesion revascularization and all-cause mortality doi.org/10.1016/j.jsca… #Cardiology #PCI #IntracoronaryImaging

Excellent teaching by David Erlinge re: Biomarkers of vulnerable plaque - plaque burden, lipid content, et al- can help predict which coronary lesions will rupture UCSD Biomarker Symposium

First 3-vessel OCT imaging study publ in JACC w/long-term FU showing OCT can identify vulnerable plaques with strong discrimination. Our editorial on whether inv imaging (OCT, NIRS-IVUS, RF-IVUS) can detect VP: "Case Closed"! There are now at least 10 good studies! Ziad Ali

Feeling stressed out? Read this new paper on stress and triggers in MI from Anneli Olsson and colleagues David S David Erlinge Troels Yndigegn MD PhD Matthias Götberg

An area of Lp(a) research that is lacking is outcomes post PCI/CABG. Data suggests pts with ⏫ Lp(a) have worse outcomes. Harpreet Bhatia David Erlinge and I outline 2 trials, one pragmatic, to assess if outcomes can be improved. TY to Journal of Clinical Lipidology for opportunity to share thoughts

Use of AI to integrate plaque composition characteristics that increase risk for ACS 1. delta FFR across lesion 2. Plaque location & burden at site 3. Total plaque volume 4. Low attenuation plaque volume 5. Percent myocardial blood flow Lumen narrowing not as important !!

Sanjay Kaul Ole Fröbert John Mandrola, MD The REDUCE-AMI trial is the only trial powered to guide decision in post MI-patients with LV =/>50%. The KM-curves are virtually overlapping and if cross-over was supposed to affect the result one would expect an early delta which would disappear and this is not the case.

Download slides for PREVENT trial on PCI + OMT in reducing MACE in non-flow-limiting vulnerable plaques. Link here: shorturl.at/ijqAM

After the PREVENT trial, regarding PCI of vulnerable plaque, will you:

I am passionate about neutral studies, but only when their results are true negatives, not false negatives due to low statistical power. I particularly appreciate them when they eliminate drugs with seemingly routine indications but are actually poorly supported by literature or

🚨INFINITY-SWEDEHEART: #DynamX® Bioadaptor meets primary endpoint and significantly reduces adverse events vs. DES after six months! Full data: businesswire.com/news/home/2024… CE marked. Not for sale in the U.S. #cardiotwitter #ESC2024 PMN 2001 REV A

Our latest PROSPECT II pub in Circ CV Int supports a possible use for NIRS during PCI. FU stent edge–related MACE was ↑ if post-PCI stent edge maxLCBI4mm was >~100 with stent edge plaque burden >50% (adj OR 4.11). Suggests slightly longer stents to cover lipid MAY ↓MACE.

🔬 Get ready for the latest in cardiovascular research! Dr. David Erlinge will reveal findings from the INFINITY-SWEDEHEART trial on Monday, October 28. Be part of the first to see major clinical trials and transformative science at #TCT2024! Claim your spot today:

Please see the results of our INFINITY-SWEDEHEART trial in Lancet. authors.elsevier.com/a/1j-ys_3CjG8u…

Congratulations to Troels Yndigegn MD PhD for a successful defence of his PhD today (1st author of REDUCE-AMI trial doi.org/10.1056/nejmoa… ) at the University of Lund (I was the external examiner) with supervisors Alexandru Schiopu and David Erlinge This was a public examination with a